Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Improved PDX and CDX Data Processing-Letter.

Ahdesmäki MJ.

Mol Cancer Res. 2018 Nov;16(11):1813. doi: 10.1158/1541-7786.MCR-18-0534. No abstract available.

PMID:
30385665
2.

Correction: Altered regulation and expression of genes by BET family of proteins in COPD patients.

Malhotra R, Kurian N, Zhou XH, Jiang F, Monkley S, DeMicco A, Clausen IG, Dellgren G, Edenro G, Ahdesmäki MJ, Clausen M, Öberg L, Israelsson E, Belfield G, Vaarala O.

PLoS One. 2017 Apr 12;12(4):e0175997. doi: 10.1371/journal.pone.0175997. eCollection 2017.

3.

Prioritisation of structural variant calls in cancer genomes.

Ahdesmäki MJ, Chapman BA, Cingolani P, Hofmann O, Sidoruk A, Lai Z, Zakharov G, Rodichenko M, Alperovich M, Jenkins D, Carr TH, Stetson D, Dougherty B, Barrett JC, Johnson JH.

PeerJ. 2017 Apr 4;5:e3166. doi: 10.7717/peerj.3166. eCollection 2017.

4.

Altered regulation and expression of genes by BET family of proteins in COPD patients.

Malhotra R, Kurian N, Zhou XH, Jiang F, Monkley S, DeMicco A, Clausen IG, Dellgren G, Edenro G, Ahdesmäki MJ, Clausen M, Öberg L, Israelsson E, Belfield G, Vaarala O.

PLoS One. 2017 Mar 1;12(3):e0173115. doi: 10.1371/journal.pone.0173115. eCollection 2017. Erratum in: PLoS One. 2017 Apr 12;12 (4):e0175997. Delgren G [corrected to Dellgren G].

5.

Disambiguate: An open-source application for disambiguating two species in next generation sequencing data from grafted samples.

Ahdesmäki MJ, Gray SR, Johnson JH, Lai Z.

Version 2. F1000Res. 2016 Nov 22 [revised 2017 Jan 1];5:2741. doi: 10.12688/f1000research.10082.2. eCollection 2016.

6.

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.

Mosely SI, Prime JE, Sainson RC, Koopmann JO, Wang DY, Greenawalt DM, Ahdesmaki MJ, Leyland R, Mullins S, Pacelli L, Marcus D, Anderton J, Watkins A, Coates Ulrichsen J, Brohawn P, Higgs BW, McCourt M, Jones H, Harper JA, Morrow M, Valge-Archer V, Stewart R, Dovedi SJ, Wilkinson RW.

Cancer Immunol Res. 2017 Jan;5(1):29-41. doi: 10.1158/2326-6066.CIR-16-0114. Epub 2016 Dec 6.

7.

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.

Rhyasen GW, Hattersley MM, Yao Y, Dulak A, Wang W, Petteruti P, Dale IL, Boiko S, Cheung T, Zhang J, Wen S, Castriotta L, Lawson D, Collins M, Bao L, Ahdesmaki MJ, Walker G, O'Connor G, Yeh TC, Rabow AA, Dry JR, Reimer C, Lyne P, Mills GB, Fawell SE, Waring MJ, Zinda M, Clark E, Chen H.

Mol Cancer Ther. 2016 Nov;15(11):2563-2574. Epub 2016 Aug 29.

8.

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

Eberlein CA, Stetson D, Markovets AA, Al-Kadhimi KJ, Lai Z, Fisher PR, Meador CB, Spitzler P, Ichihara E, Ross SJ, Ahdesmaki MJ, Ahmed A, Ratcliffe LE, O'Brien EL, Barnes CH, Brown H, Smith PD, Dry JR, Beran G, Thress KS, Dougherty B, Pao W, Cross DA.

Cancer Res. 2015 Jun 15;75(12):2489-500. doi: 10.1158/0008-5472.CAN-14-3167. Epub 2015 Apr 13.

Supplemental Content

Loading ...
Support Center